MET18 Antibody

What is MET18 and why is it important to study with antibodies?

MET18 is a conserved component of the cytosolic iron-sulfur cluster assembly (CIA) pathway in eukaryotes that plays a critical role in epigenetic regulation. It is particularly involved in active DNA demethylation processes by affecting the enzymatic activity of ROS1, a DNA demethylase . MET18 dysfunction leads to hypermethylation at thousands of genomic loci, significantly overlapping with hypermethylated regions identified in ros1 and ros1dml2dml3 mutants . Using antibodies against MET18 allows researchers to study its expression patterns, cellular localization, protein-protein interactions, and role in various biological processes, particularly in epigenetic regulation pathways.

What are the common applications of MET18 antibodies in molecular biology research?

MET18 antibodies can be utilized in several standard molecular biology techniques:

• Western blotting: For detecting and quantifying MET18 protein expression in different tissues or under various experimental conditions

• Immunoprecipitation (IP): For isolating MET18 protein complexes to identify interacting partners

• Chromatin immunoprecipitation (ChIP): For examining if MET18 associates with chromatin

• Immunofluorescence (IF): For studying subcellular localization of MET18

• Immunohistochemistry (IHC): For examining MET18 expression patterns in tissue sections

Each application requires specific optimization of antibody dilution, incubation conditions, and detection methods to ensure reliable results, particularly when studying proteins involved in complex processes like epigenetic regulation .

How should MET18 antibodies be validated before use in critical experiments?

Before using MET18 antibodies in critical experiments, researchers should validate them through multiple approaches:

• Positive and negative controls: Testing the antibody in samples with known MET18 expression levels, including knockout/knockdown models where available

• Multiple detection methods: Confirming specificity using different techniques (Western blot, IP, IF)

• Peptide competition assay: Preincubating the antibody with the immunizing peptide should block specific binding

• Cross-reactivity testing: Ensuring the antibody doesn't recognize related proteins, especially other CIA pathway components

• Literature comparison: Validating that observed patterns match published data on MET18 expression and localization

For MET18 specifically, testing the antibody in met18 mutant plants versus wild-type provides an excellent negative control to confirm specificity, as demonstrated in studies examining MET18's role in DNA demethylation .

How can MET18 antibodies be used to investigate the CIA pathway's role in DNA demethylation?

To investigate the CIA pathway's role in DNA demethylation using MET18 antibodies, researchers can design experiments that examine:

• Co-immunoprecipitation studies: Using MET18 antibodies to pull down protein complexes and identify interactions with DNA demethylases like ROS1 and other CIA components (CIA1, CIA2/AE7, NAR1, and AtDRE2)

• ChIP-seq analysis: Determining genomic regions where MET18 may associate with chromatin to facilitate DNA demethylation

• Proximity ligation assays: Visualizing direct interactions between MET18 and ROS1 in situ

• Immunofluorescence co-localization: Examining whether MET18 co-localizes with ROS1 and other DNA demethylation machinery components in the nucleus

A comprehensive experimental approach would combine these methods with functional assays comparing wild-type and met18 mutant plants, analyzing DNA methylation patterns at known ROS1 target loci .

What considerations are important when designing immunoblotting protocols for MET18 detection?

When designing immunoblotting protocols for MET18 detection, consider the following:

• Sample preparation:

  • Use appropriate extraction buffers containing protease inhibitors

  • Include reducing agents to break disulfide bonds if working with iron-sulfur cluster-associated proteins

  • Consider nuclear extraction protocols as MET18 functions in DNA demethylation

• Gel electrophoresis conditions:

  • Select appropriate percentage of acrylamide based on MET18's molecular weight

  • Consider gradient gels to improve resolution

• Transfer conditions:

  • Optimize transfer time and voltage for efficient transfer of MET18

  • Consider wet transfer for larger proteins

• Blocking and antibody incubation:

  • Test different blocking reagents (BSA vs. milk) as milk may contain phosphatases that interfere with some epitopes

  • Optimize primary antibody dilution and incubation time/temperature

  • Include appropriate controls including knockout/knockdown samples

• Signal detection:

  • Choose detection methods with appropriate sensitivity for expected expression levels

For MET18 specifically, careful sample preparation is critical as it interacts with iron-sulfur clusters which can be sensitive to oxidation during extraction procedures .

What are the optimal fixation and permeabilization conditions for MET18 immunofluorescence studies?

For optimal MET18 immunofluorescence studies, consider the following fixation and permeabilization conditions:

• Fixation options:

  • 4% paraformaldehyde (10-15 minutes): Preserves protein structure while maintaining antigenicity

  • Methanol fixation (-20°C, 10 minutes): May better expose nuclear proteins but can distort some epitopes

  • Combined fixation: 2% paraformaldehyde followed by methanol for proteins with both cytoplasmic and nuclear localization

• Permeabilization approaches:

  • For paraformaldehyde-fixed samples: 0.1-0.5% Triton X-100 (10 minutes)

  • For nuclear proteins: Consider 0.5% Triton X-100 or 0.1% SDS for enhanced nuclear permeabilization

  • Digitonin (50 μg/ml): For selective plasma membrane permeabilization if studying cytoplasmic vs. nuclear distribution

• Optimization considerations:

  • Test multiple conditions as MET18's role in the CIA pathway and DNA demethylation suggests both nuclear and cytoplasmic localization

  • Include antigen retrieval steps if necessary

  • Consider epitope masking that might occur during fixation

Based on MET18's known interaction with ROS1 DNA demethylase, nuclear localization is expected, so fixation conditions preserving nuclear structure while allowing antibody access are critical .

How can MET18 antibodies be utilized to study its interaction with ROS1 and other DNA demethylation machinery?

MET18 antibodies can be employed in several advanced techniques to study its interactions with ROS1 and other DNA demethylation components:

• Sequential ChIP (Re-ChIP): Perform ChIP first with ROS1 antibodies, then with MET18 antibodies to identify genomic regions where both proteins co-localize

• Proximity-dependent biotin identification (BioID): Fuse MET18 to a biotin ligase and identify proteins in close proximity, confirming results with co-IP using MET18 antibodies

• Fluorescence resonance energy transfer (FRET): Tag MET18 and ROS1 with appropriate fluorophores and measure energy transfer as an indicator of direct interaction, validating with antibody-based techniques

• In situ proximity ligation assay (PLA): Use primary antibodies against MET18 and ROS1 followed by oligonucleotide-linked secondary antibodies to visualize direct interactions through fluorescent signal generation when proteins are in close proximity

• Quantitative co-immunoprecipitation: Use standardized amounts of MET18 antibodies to pull down protein complexes, then perform quantitative analysis of co-precipitated ROS1 and other CIA components under different conditions

Research indicates that MET18 directly interacts with ROS1 and affects its enzymatic activity through the iron-sulfur cluster, making these interaction studies particularly valuable for understanding the mechanism of active DNA demethylation .

What methodological approaches can address potential epitope masking when MET18 forms protein complexes?

When studying MET18 using antibodies, epitope masking can occur when MET18 forms complexes with ROS1, CIA components, or other proteins. To address this challenge:

• Use multiple antibodies targeting different epitopes:

  • N-terminal vs. C-terminal epitopes

  • Internal domain-specific antibodies

  • Compare results across antibodies to identify regions frequently masked in complexes

• Modify immunoprecipitation conditions:

  • Test different detergents (NP-40, Triton X-100, CHAPS) at various concentrations

  • Adjust salt concentrations to preserve interactions or disrupt weaker associations

  • Try mild crosslinking to stabilize transient interactions before antibody application

• Apply protein complex disruption techniques:

  • Sonication or mild heating

  • Graduated stringency washes

  • Limited proteolysis to expose hidden epitopes

• Consider native vs. denaturing conditions:

  • Native PAGE followed by immunoblotting can identify shifts in migration due to complex formation

  • Compare results with denaturing conditions to identify differences in detection

Since MET18 has been shown to interact with multiple proteins including ROS1, CIA1, CIA2/AE7, NAR1, and AtDRE2, understanding potential masking effects is crucial for accurate interpretation of antibody-based experimental results .

How can researchers differentiate between free MET18 and MET18 bound in the CIA targeting complex using antibody-based techniques?

Differentiating between free MET18 and MET18 bound in CIA targeting complexes requires specialized antibody-based approaches:

• Size exclusion chromatography followed by immunoblotting:

  • Fractionate cell extracts based on molecular size

  • Perform Western blotting on fractions using MET18 antibodies

  • Compare elution profiles with known CIA complex components

  • Free MET18 will appear in fractions corresponding to its individual molecular weight, while complex-bound MET18 will appear in higher molecular weight fractions

• Sucrose gradient ultracentrifugation with immunodetection:

  • Separate protein complexes based on sedimentation coefficient

  • Analyze fractions by immunoblotting for MET18

  • Compare distribution with other CIA components like CIA1 and CIA2/AE7

• Blue native PAGE with antibody detection:

  • Separate native protein complexes

  • Use second-dimension SDS-PAGE followed by immunoblotting

  • Identify spots corresponding to free vs. complex-bound MET18

• Quantitative immunoprecipitation:

  • Use antibodies against CIA components to pull down complexes

  • Quantify the proportion of total MET18 that co-precipitates

This approach is particularly relevant since research indicates MET18, CIA1, and CIA2/AE7 form a targeting complex with a 1:1:1 stoichiometry, making it important to distinguish free vs. complex-bound forms when studying MET18 function .

What are common sources of false positive or negative results when using MET18 antibodies, and how can they be addressed?

When working with MET18 antibodies, several issues can lead to false results:

Common sources of false positives:

• Cross-reactivity with related proteins:

  • Solution: Validate antibody specificity using met18 mutant tissues as negative controls

  • Perform peptide competition assays

• Non-specific binding:

  • Solution: Optimize blocking conditions (try different blocking agents like BSA, milk, or commercial blockers)

  • Increase washing stringency and duration

• High background in immunofluorescence:

  • Solution: Adjust fixation conditions and antibody concentration

  • Include appropriate controls (secondary antibody only, isotype controls)

Common sources of false negatives:

• Epitope masking due to protein interactions:

  • Solution: Try different antibodies targeting various regions of MET18

  • Modify extraction conditions to disrupt protein complexes

• Low sensitivity:

  • Solution: Employ signal amplification techniques (HRP-conjugated polymers, tyramide signal amplification)

  • Optimize antigen retrieval methods

• Protein degradation:

  • Solution: Use fresh samples and include protease inhibitors

  • Optimize sample preparation to preserve MET18 integrity

Targeted validation approaches are particularly important given MET18's known interactions with other CIA pathway proteins and its role in iron-sulfur cluster transfer, which could affect epitope accessibility in different experimental contexts .

How should researchers interpret discrepancies between MET18 antibody results and gene expression data?

When researchers encounter discrepancies between MET18 protein levels (detected by antibodies) and gene expression data, several interpretations and approaches should be considered:

• Post-transcriptional regulation:

  • MET18 protein may be subject to regulation at the translational level

  • Compare protein half-life with mRNA degradation rates

  • Examine microRNA binding sites in MET18 mRNA that might affect translation

• Post-translational modifications and stability:

  • Investigate if MET18 undergoes proteolytic processing, ubiquitination, or other modifications

  • Test if stabilization of MET18 protein (using proteasome inhibitors) resolves discrepancies

• Antibody limitations:

  • Determine if the antibody recognizes all isoforms/modified forms of MET18

  • Test multiple antibodies targeting different epitopes

• Contextual considerations:

  • Examine if discrepancies occur in specific tissues or conditions

  • Consider if iron-sulfur cluster assembly/loading affects antibody recognition

• Validation approaches:

  • Express tagged versions of MET18 and compare endogenous detection with tag detection

  • Perform pulse-chase experiments to measure protein turnover rates

Studies of MET18's role in DNA demethylation have shown that while met18 mutation affects DNA methylation patterns similar to ros1 mutation, there are also MET18-specific effects, indicating complex regulation that might explain potential discrepancies between transcript and protein levels .

What controls should be included when using MET18 antibodies to study iron-sulfur cluster transfer to client proteins?

When studying iron-sulfur cluster transfer from MET18 to client proteins like ROS1, include these essential controls:

• Genetic controls:

  • met18 mutant samples (negative control)

  • Samples expressing MET18 variants with mutations in iron-sulfur cluster binding domains

  • Samples with CIA pathway mutations upstream of MET18 (should affect MET18 function)

• Biochemical controls:

  • Iron chelator treatments to disrupt iron-sulfur clusters

  • Reducing/oxidizing conditions to test iron-sulfur cluster stability

  • Point mutants in the conserved iron-sulfur binding motif of client proteins (e.g., ROS1)

• Interaction controls:

  • Competitive binding assays with known MET18 client proteins

  • Step-wise assembly of the CIA targeting complex

  • Sequential immunoprecipitations to distinguish direct vs. indirect interactions

• Functional readouts:

  • Activity assays for client proteins (e.g., DNA demethylation activity for ROS1)

  • Iron-sulfur cluster occupancy measurements

These controls are particularly important given research showing that point mutations in the conserved iron-sulfur binding motif of ROS1 disrupted its enzymatic activity, and that MET18 directly interacts with ROS1, likely transferring the iron-sulfur cluster required for ROS1 function .

How can MET18 antibodies be used to investigate the relationship between iron-sulfur cluster assembly and genome-wide DNA methylation patterns?

To investigate the relationship between iron-sulfur cluster assembly and DNA methylation using MET18 antibodies, researchers can implement a multi-faceted approach:

• ChIP-seq with MET18 antibodies combined with whole-genome bisulfite sequencing (WGBS):

  • Perform ChIP-seq with MET18 antibodies to identify genomic binding sites

  • Conduct WGBS in wild-type and met18 mutants to correlate MET18 binding with methylation changes

  • Create overlay maps showing the relationship between MET18 binding and differential methylation regions (DMRs)

• Immunoprecipitation-mass spectrometry under different iron availability conditions:

  • Use MET18 antibodies to pull down protein complexes under iron-replete and iron-deficient conditions

  • Identify changes in MET18-associated proteins using mass spectrometry

  • Correlate these changes with alterations in DNA methylation patterns

• Proximity-based labeling combined with methylome analysis:

  • Express MET18 fused to a proximity labeling enzyme (BioID or APEX)

  • Identify proteins in proximity to MET18 under different conditions

  • Correlate the composition of MET18 protein complexes with changes in DNA methylation

This approach is particularly relevant given that met18 mutants display DNA hypermethylation at thousands of genomic loci, with approximately 70% overlapping with ros1 or rdd mutant hypermethylated regions, suggesting a mechanistic link between iron-sulfur cluster assembly and DNA demethylation .

What methodological approaches can resolve contradictory data regarding MET18's role in both DNA hypermethylation and hypomethylation?

To resolve contradictory findings regarding MET18's dual role in both DNA hypermethylation and hypomethylation, researchers should implement these methodological approaches:

• Locus-specific analysis with methylation-sensitive techniques:

  • Perform methylation-sensitive PCR (Chop-PCR) at specific loci

  • Use bisulfite sequencing to obtain single-base resolution

  • Compare results across multiple genetic backgrounds (met18 single mutants vs. met18 combined with various DNA methylation pathway mutants)

• Context-specific methylation analysis:

  • Separately analyze CG, CHG, and CHH methylation contexts

  • Determine if MET18's effects are context-dependent

  • Create a comprehensive table showing context-specific effects:

• Genetic interaction studies:

  • Generate double mutants between met18 and components of both:

    • Active DNA demethylation (e.g., ros1, dml2, dml3)

    • DNA methylation pathways (e.g., drm2, cmt3)

  • Use antibodies to detect protein interactions in these backgrounds

• Time-course analysis:

  • Track methylation changes over developmental time in met18 mutants

  • Determine if hypermethylation and hypomethylation are temporally separated events

Research has shown that met18 mutants display both DNA hypermethylation at many loci and hypomethylation at others (particularly in the CHH context at TE regions), indicating a complex role for MET18 in regulating both DNA demethylation and methylation pathways .

How can researchers leverage MET18 antibodies to investigate tissue-specific differences in iron-sulfur cluster-dependent epigenetic regulation?

To investigate tissue-specific differences in iron-sulfur cluster-dependent epigenetic regulation using MET18 antibodies, researchers can employ these advanced approaches:

• Tissue-specific immunohistochemistry and immunofluorescence:

  • Use MET18 antibodies to map expression patterns across tissues

  • Combine with markers for active DNA demethylation (e.g., ROS1)

  • Correlate expression patterns with tissue-specific methylation data

• Laser capture microdissection combined with antibody-based techniques:

  • Isolate specific cell types or tissues

  • Perform immunoprecipitation followed by mass spectrometry to identify tissue-specific MET18 interaction partners

  • Compare MET18 complex composition across tissues

• Single-cell approaches:

  • Develop protocols for single-cell immunofluorescence to detect MET18

  • Combine with single-cell bisulfite sequencing to correlate MET18 presence with methylation patterns at the cellular level

• Tissue-specific genetic complementation:

  • Express MET18 under tissue-specific promoters in met18 mutant backgrounds

  • Use MET18 antibodies to confirm expression

  • Analyze restoration of normal methylation patterns in complemented tissues

These approaches would be particularly valuable given the findings that MET18 affects both DNA demethylation and methylation pathways, which may have tissue-specific requirements or functions in different developmental contexts .

What are the key considerations when selecting between polyclonal and monoclonal MET18 antibodies for different applications?

When choosing between polyclonal and monoclonal MET18 antibodies, researchers should consider application-specific factors:

Polyclonal MET18 Antibodies:

Advantages:

• Recognize multiple epitopes, increasing detection sensitivity

• More tolerant of minor protein denaturation or modifications

• Better for detecting low-abundance proteins

• Typically work well across applications (Western blot, IP, IHC)

Best applications:

• Initial characterization of MET18 expression

• Immunoprecipitation of MET18 complexes

• Detection of MET18 in fixed tissues

Limitations:

• Batch-to-batch variation

• Potential for higher background

• Less specificity for closely related proteins

Monoclonal MET18 Antibodies:

Advantages:

• Consistent performance across experiments

• Higher specificity for a single epitope

• Reduced background in some applications

• Better for quantitative studies

Best applications:

• Quantitative Western blotting

• Super-resolution microscopy

• Flow cytometry

• Applications requiring high reproducibility

Limitations:

• May lose reactivity if the single epitope is masked or modified

• Sometimes less sensitive than polyclonals

For studying MET18's role in iron-sulfur cluster transfer to client proteins like ROS1, consider using both types: polyclonal antibodies for complex immunoprecipitation and monoclonal antibodies for specific detection of interaction domains .

What modifications to standard protocols are necessary when using MET18 antibodies in plants versus mammalian systems?

When adapting protocols for MET18 antibodies between plant and mammalian systems, researchers should consider these modifications:

Sample Preparation Differences:

• Cell wall considerations (plants):

  • Include cell wall digestion steps (cellulase, macerozyme) for protoplast preparation

  • Use stronger homogenization methods to disrupt plant tissues

  • Consider specialized buffers containing PVPP to remove phenolic compounds

• Protein extraction modifications:

  • Plant tissues: Include reducing agents (DTT, β-mercaptoethanol) to counter oxidative enzymes

  • Mammalian cells: Gentler lysis conditions may be sufficient

  • Optimize detergent concentrations (higher for plants, lower for mammalian cells)

Immunoprecipitation Adjustments:

• Pre-clearing modifications:

  • Plants: More extensive pre-clearing to remove components that cause non-specific binding

  • Mammalian systems: Standard pre-clearing protocols usually sufficient

• Washing stringency:

  • Plants: May require higher salt concentrations in wash buffers

  • Mammalian systems: Standard washing conditions generally effective

Immunofluorescence Adaptations:

• Fixation differences:

  • Plants: Longer fixation times due to cell wall presence

  • Mammalian cells: Standard 10-15 minute PFA fixation protocols

• Permeabilization:

  • Plants: Higher detergent concentrations (0.5-1% Triton X-100)

  • Mammalian cells: Lower detergent concentrations (0.1-0.3% Triton X-100)

Most published studies on MET18 and its role in iron-sulfur cluster assembly and DNA demethylation have been conducted in plant systems, particularly Arabidopsis, where MET18 has been shown to interact with ROS1 and affect genome-wide DNA methylation patterns .

What are the methodological considerations for using MET18 antibodies in ChIP-seq experiments to map genome-wide binding patterns?

When designing ChIP-seq experiments with MET18 antibodies to map genome-wide binding patterns, researchers should consider these methodological aspects:

• Antibody validation for ChIP applications:

  • Perform preliminary ChIP-qPCR at known target regions before proceeding to sequencing

  • Compare multiple antibodies targeting different MET18 epitopes

  • Include met18 mutant tissues as negative controls

  • Optimize antibody concentration specifically for ChIP (typically higher than for Western blotting)

• Crosslinking optimization:

  • Test different formaldehyde concentrations (0.5-2%)

  • Consider dual crosslinking (formaldehyde plus a protein-protein crosslinker like DSG or EGS)

  • Optimize crosslinking time (5-20 minutes) to capture transient interactions

  • Explore native ChIP options if crosslinking disrupts the iron-sulfur cluster

• Sonication parameters:

  • Carefully optimize sonication conditions to obtain 200-500 bp fragments

  • Consider enzymatic fragmentation alternatives

  • Verify fragmentation efficiency by gel electrophoresis

• Specialized considerations for MET18:

  • Include CIA complex components as positive controls

  • Consider parallel ChIP for ROS1 to identify co-occupied regions

  • Design bioinformatic analyses to identify relationships with DNA methylation patterns

• Data analysis considerations:

  • Compare MET18 binding with whole-genome bisulfite sequencing data

  • Analyze relationship between MET18 binding and differentially methylated regions (DMRs)

  • Examine co-occurrence with active DNA demethylation machinery

Since MET18 functions in iron-sulfur cluster transfer to proteins like ROS1 and is involved in DNA demethylation processes, ChIP-seq experiments can provide valuable insights into the genomic regions where these processes are actively regulated .

How can antibody-based approaches be combined with CRISPR technology to study MET18 function?

Integrating antibody-based approaches with CRISPR technology offers powerful new strategies for studying MET18 function:

• CRISPR knock-in of epitope tags for improved antibody detection:

  • Generate endogenous tagging of MET18 (FLAG, HA, or GFP tags)

  • Use well-characterized tag antibodies for detection

  • Compare results with native MET18 antibodies to validate findings

  • Create domain-specific tags to study different functional regions

• CRISPR-mediated protein tracking with antibody validation:

  • Deploy CRISPR-based visualization systems (e.g., CRISPR-Sirius)

  • Validate localization patterns with conventional MET18 immunofluorescence

  • Compare dynamics in living cells vs. fixed specimens

• Engineered mutations with antibody-based functional readouts:

  • Generate precise mutations in MET18 domains involved in iron-sulfur cluster binding/transfer

  • Use antibodies to assess protein stability, localization, and interaction partners

  • Create a table correlating mutations with functional outcomes:

• CRISPR screens with antibody-based phenotypic readouts:

  • Perform CRISPR screens targeting genes potentially involved in MET18 function

  • Use MET18 antibodies to assess effects on protein levels, complex formation

  • Identify new factors affecting iron-sulfur cluster assembly and transfer

These integrated approaches would be particularly valuable for understanding the mechanistic details of how MET18 interacts with ROS1 and other iron-sulfur cluster client proteins to regulate DNA demethylation .

What methodological strategies can help investigate potential non-canonical functions of MET18 beyond iron-sulfur cluster assembly?

To uncover potential non-canonical functions of MET18 beyond its established role in iron-sulfur cluster assembly, researchers can deploy these methodological strategies:

• Unbiased protein interaction screening with antibody-based validation:

  • Perform BioID or APEX proximity labeling with MET18 as bait

  • Validate novel interactions using co-immunoprecipitation with MET18 antibodies

  • Conduct interaction studies under conditions that inhibit iron-sulfur cluster formation

• Subcellular compartment-specific analysis:

  • Perform fractionation of cellular compartments

  • Use MET18 antibodies to detect distribution across fractions

  • Identify compartment-specific interaction partners

  • Investigate potential shuttling between compartments under different conditions

• Condition-dependent functional assessment:

  • Compare MET18 interactome under various stress conditions

  • Analyze MET18 post-translational modifications using modification-specific antibodies

  • Examine condition-specific changes in localization

• Domain-specific functional analysis:

  • Generate domain deletion/mutation constructs of MET18

  • Use antibodies to assess effects on interactions beyond CIA pathway proteins

  • Identify domains involved in potential moonlighting functions

The observation that met18 mutants display both DNA hypermethylation (overlapping with ros1 targets) and hypomethylation (particularly at transposable elements) suggests MET18 may have functions beyond simply transferring iron-sulfur clusters to DNA demethylases, potentially playing roles in multiple epigenetic regulatory pathways .

How can MET18 antibodies be used to investigate the crosstalk between iron homeostasis and epigenetic regulation?

To investigate the crosstalk between iron homeostasis and epigenetic regulation using MET18 antibodies, researchers can implement these methodological approaches:

• Iron availability experiments with antibody-based readouts:

  • Culture cells/plants under iron-deficient, normal, and iron-excess conditions

  • Use MET18 antibodies to assess:

    • Changes in protein levels

    • Alterations in subcellular localization

    • Modifications to protein-protein interactions

  • Correlate findings with genome-wide DNA methylation analysis

• Time-course studies following iron status changes:

  • Track the temporal relationship between iron availability, MET18 status, and DNA methylation

  • Use antibodies to detect rapid changes in MET18 complex formation

  • Monitor recruitment to chromatin using ChIP approaches

• Multi-omics integration:

  • Combine MET18 ChIP-seq data with:

    • RNA-seq under varying iron conditions

    • Whole-genome bisulfite sequencing

    • Metabolomic data focusing on iron-related metabolites

  • Create comprehensive models of how iron status affects MET18 function and epigenetic outcomes

• In vitro reconstitution with purified components:

  • Establish in vitro systems to study iron-sulfur cluster transfer

  • Use antibodies to monitor complex formation and stability

  • Test how varying iron concentrations affect MET18's ability to transfer clusters to client proteins

This research direction is particularly compelling given that MET18 connects iron metabolism (through iron-sulfur cluster assembly) with epigenetic regulation (through DNA demethylation), potentially serving as a key sensor linking cellular iron status to genome regulation .

What quality control metrics should be applied when validating new lots of MET18 antibodies for research use?

When validating new lots of MET18 antibodies, researchers should implement these rigorous quality control metrics:

• Specificity validation:

  • Western blot comparison with previous lots

  • Testing in wild-type vs. met18 mutant/knockout backgrounds

  • Peptide competition assays

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

• Sensitivity assessment:

  • Titration experiments to determine minimum detection limits

  • Comparison of signal strength with reference standards

  • Signal-to-noise ratio quantification

  • Dynamic range determination

• Reproducibility testing:

  • Inter-experimenter variability assessment

  • Day-to-day variation measurement

  • Cross-platform consistency (different imaging systems, detection methods)

• Application-specific validation:

  • For Western blotting: Linear dynamic range assessment

  • For immunofluorescence: Background fluorescence comparison

  • For ChIP: Enrichment at known targets vs. negative control regions

  • For immunoprecipitation: Pull-down efficiency quantification

• Batch certification documentation:

  • Record key parameters in a standardized format

  • Create validation reports with side-by-side comparisons

  • Document optimal working concentrations for each application

These quality control metrics are particularly important for MET18 antibodies given the protein's central role in iron-sulfur cluster assembly and DNA demethylation, where reliable detection is critical for interpretation of experimental results .

How can researchers quantitatively assess antibody performance when studying low-abundance MET18 protein in different tissues?

To quantitatively assess antibody performance for detecting low-abundance MET18 protein across tissues, researchers should implement these methodological approaches:

• Absolute quantification strategies:

  • Spike-in known quantities of recombinant MET18 protein

  • Create standard curves for each tissue type

  • Use mass spectrometry with isotope-labeled peptides for absolute quantification

  • Compare antibody-based detection with absolute quantities

• Signal amplification methods comparison:

  • Test tyramide signal amplification for immunohistochemistry/immunofluorescence

  • Evaluate enhanced chemiluminescence systems for Western blotting

  • Assess quantum dot-conjugated secondary antibodies

  • Compare signal-to-noise ratios across methods

• Tissue-specific background assessment:

  • Perform parallel staining in wild-type and met18 mutant tissues

  • Quantify background signals in different tissues

  • Calculate tissue-specific detection limits

  • Develop tissue-specific protocols with optimized parameters:

• Digital quantification approaches:

  • Implement digital image analysis (pixel intensity quantification)

  • Use automated spot counting for single-molecule detection

  • Apply machine learning algorithms for pattern recognition in complex tissues

Given that MET18 plays roles in both DNA demethylation and potentially in DNA methylation regulation, its expression may vary across tissues and developmental stages, making these quantitative approaches essential for reliable comparative studies .

What are the best practices for optimizing immunoprecipitation protocols when studying MET18 interactions with DNA demethylases?

When optimizing immunoprecipitation (IP) protocols to study MET18 interactions with DNA demethylases like ROS1, researchers should follow these best practices:

• Pre-IP sample preparation optimization:

  • Test nuclear extraction protocols vs. total cell lysates

  • Compare different extraction buffers with varying salt concentrations (150-500 mM)

  • Optimize detergent types and concentrations (NP-40, Triton X-100, CHAPS)

  • Include protease inhibitors and phosphatase inhibitors to preserve interactions

• Antibody coupling strategies:

  • Compare direct antibody addition vs. pre-coupling to beads

  • Test different antibody immobilization methods (Protein A/G, direct coupling)

  • Optimize antibody-to-sample ratios

  • Consider dual IP strategies (sequential IP with MET18 then ROS1 antibodies)

• IP condition optimization:

  • Test varying incubation times (2h vs. overnight)

  • Compare different temperatures (4°C vs. room temperature)

  • Evaluate the impact of adding reducing agents or iron chelators

  • Assess the effect of crosslinking before IP

• Washing optimization:

  • Develop a graduated washing stringency protocol

  • Compare retention of interactions across wash conditions

  • Determine minimum wash conditions that maintain specific interactions

  • Consider gentle wash buffers to preserve weak or transient interactions

• Elution and detection strategies:

  • Compare specific peptide elution vs. general elution methods

  • Test native elution conditions vs. denaturing conditions

  • Optimize Western blotting protocols for detection of co-precipitated proteins

  • Consider mass spectrometry for unbiased interaction profiling

Optimized IP protocols are particularly important for studying MET18-ROS1 interactions, as research has demonstrated their direct physical association and functional relationship in the DNA demethylation pathway .